Evidence map›Paper›PMID 39352632›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions.

Bokyung Ahn, Deokhoon Kim, Mi-Ju Kim, Seo-Rin Jeong, In Hye Song, Joo Young Kim, Soon Auck Hong, Sun-Young Jun, HyungJun Cho, Young Soo Park and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bokyung AhnDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Deokhoon KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Mi-Ju KimBiomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Seo-Rin JeongDepartment of Statistics, Korea University, Seoul, Republic of Korea.
In Hye SongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Joo Young KimDepartment of Pathology, Chung‑Ang University Hospital, College of Medicine, Chung-Ang University, Seoul, Republic of Korea.
Soon Auck HongDepartment of Pathology, Chung‑Ang University Hospital, College of Medicine, Chung-Ang University, Seoul, Republic of Korea.
Sun-Young JunDepartment of Pathology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
HyungJun ChoDepartment of Statistics, Korea University, Seoul, Republic of Korea.
Young Soo ParkDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Seung-Mo HongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. smhong28@gmail.com.ORCID 0000-0002-8888-6007

Funding

Engineering HCC-selective PET agentZIABC011800 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ESCORCIA, FREDDY · 2018 to 2025
$10.6M
Asan Institute for Life Sciences, Asan Medical Center 2022IP0042NIH HHS ZIA BC 011800
6 · The paper itself

Abstract

backgroundGastric neuroendocrine carcinomas (NECs) are rare cancers with highly aggressive behavior. Although tertiary lymphoid structures (TLSs) are well-known prognostic factors in various cancers, their role in gastric NECs remain unexplored. Unique immunohistochemical subtypes of pulmonary NECs have been discovered, however, their feasibility in gastric NECs is unknown.

methodsThe presence and maturation of TLSs (lymphoid aggregates, primary and secondary follicles) were assessed in 48 surgically resected gastric NECs and were compared with immunohistochemical subtypes, using a panel of ASCL1, NeuroD1, POU2F3, YAP1, and DLL3 with three neuroendocrine (NE) markers.

resultsPatients with secondary follicles had significantly better overall survival (OS) and recurrence-free survival (RFS; both, p = 0.004) than those without them. Based on the hierarchical clustering, gastric NECs were classified into all low/negative (31%), high-YAP1 (19%), high-DLL3/low-NE (29%), and high-NE (21%) expression groups. The high-DLL3/low-NE group was associated with absent TLSs (p = 0.026) and showed the worst OS (p = 0.026). Distant metastasis and a lack of secondary follicles were poor independent prognostic factors of OS and RFS.

conclusionThe assessment of TLSs is a feasible and potent biomarker for gastric NECs, thus enabling better prognosis and more effective immunotherapy. Furthermore, gastric NECs can be categorized as four immunohistochemically distinct groups, of which the high-DLL3/low-NE group has the worst OS with lack of TLSs.

Indexed as

Biomarkers, TumorCarcinoma, NeuroendocrineStomach NeoplasmsTertiary Lymphoid StructuresAdultAgedAged, 80 and overFemaleHumansIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsMiddle AgedPrognosisBiomarkers, TumorDLL3 protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsGastricMolecular subgroupNeuroendocrine carcinomaPrognosisTertiary lymphoid structure

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.